Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways
| Autor: | Axelrod, Mark J., Mendez, Rolando E., Khalil, Ashraf, Leimgruber, Stephanie S., Sharlow, Elizabeth R., Capaldo, Brian, Conaway, Mark, Gioeli, Daniel G., Weber, Michael J., Jameson, Mark J. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Triazines
Cell Culture Techniques Dasatinib Apoptosis Drug Synergism Article Receptor IGF Type 1 Drug Resistance Neoplasm Head and Neck Neoplasms Cell Line Tumor Antineoplastic Combined Chemotherapy Protocols Carcinoma Squamous Cell Humans Pyrazoles Carbamates Phosphorylation Proto-Oncogene Proteins c-akt Signal Transduction |
| Zdroj: | Head Neck |
| Popis: | BACKGROUND. In head and neck squamous cell carcinoma (HNSCC), resistance to single-agent targeted therapy may be overcome by co-targeting of compensatory signaling pathways. METHODS. A targeted drug screen with 120 combinations was used on 9 HNSCC cell lines. RESULTS. Multiple novel drug combinations demonstrated synergistic growth inhibition. Combining the insulin-like growth factor-1 receptor (IGF-1R) inhibitor, BMS754807, with either the human epidermal growth factor receptor (HER)-family inhibitor, BMS599626, or the Src-family kinase inhibitor, dasatinib, resulted in substantial synergy and growth inhibition. Depending on the cell line, these combinations induced synergistic or additive apoptosis; when synergistic apoptosis was observed, AKT phosphorylation was inhibited to a greater extent than either drug alone. Conversely, when additive apoptosis occurred, AKT phosphorylation was not reduced by the drug combination. CONCLUSION. Combined IGF-1R/HER family and IGF-1R/Src family inhibition may have therapeutic potential in HNSCC. AKT may be a node of convergence between IGF-1R signaling and pathways that compensate for IGF-1R inhibition. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|